Reviewing BioNexus Gene Lab (NASDAQ:BGLC) & Selectis Health (OTCMKTS:GBCS)

Selectis Health (OTCMKTS:GBCS) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Profitability

This table compares Selectis Health and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Selectis Health	-2.45%	N/A	-3.03%
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Earnings & Valuation

This table compares Selectis Health and BioNexus Gene Lab”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Selectis Health	$41.44 million	0.39	-$1.02 million	($0.34)	-15.32
BioNexus Gene Lab	$7.43 million	0.59	-$2.98 million	($1.48)	-1.22

Selectis Health has higher revenue and earnings than BioNexus Gene Lab. Selectis Health is trading at a lower price-to-earnings ratio than BioNexus Gene Lab, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Selectis Health and BioNexus Gene Lab, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Selectis Health	0	0	0	0	0.00
BioNexus Gene Lab	1	0	0	0	1.00

Insider & Institutional Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. 15.2% of Selectis Health shares are held by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Selectis Health has a beta of -1.07, indicating that its stock price is 207% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.08, indicating that its stock price is 308% more volatile than the S&P 500.

Summary

Selectis Health beats BioNexus Gene Lab on 7 of the 12 factors compared between the two stocks.

About Selectis Health

Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.